Supply of Progestogen-Only Long-Acting Intraurine Systems

Details

Tender Closed
RFx ID :	16331546
Tender Name :	Supply of Progestogen-Only Long-Acting Intraurine Systems
Reference # :	A800426
Open Date :	Friday, 11 September 2015 3:00 PM (Pacific/Auckland UTC+12:00)
Close Date  :	Friday, 16 October 2015 4:00 PM (Pacific/Auckland UTC+13:00)
Tender Type :	Request for Proposals (RFP)
Tender Coverage :	Sole Agency  [?]
Categories :	51000000 - Drugs and Pharmaceutical Products
Regions:	New Zealand
Exemption Reason :	None
Required Pre-qualifications :	None
Contact :	Bronwyn Hale bronwyn.hale@pharmac.govt.nz 04 901 3239
Alternate Physical Delivery Address  :
Alternate Physical Fax Number  :
Agency Address :

PHARMAC invites proposals for the supply of progestogen-only long-acting intrauterine systems in New Zealand.

PHARMAC is interested in considering proposals from suppliers of progestogen-only long-acting reversible contraceptives in the presentation of an intrauterine system.

This would include a levonorgestrel intrauterine system, as levonorgestrel is a synthetic progestogen, but would not include any non-progestogen containing intrauterine devices or levonorgestrel implants.

Proposals must be submitted to PHARMAC no later than 4.00 p.m. (New Zealand time) on 16 October 2015, via the Government Electronic Tenders Service (GETS). Late proposals will only be considered at PHARMAC’s discretion.

If you have any inquiries about this RFP you should submit them on GETS or alternatively contact Bronwyn Hale, Therapeutic Group Manager by email at bronwyn.hale@pharmac.govt.nz.

This tender has been awarded to:

• Bayer New Zealand Ltd

Further Award Information:
PHARMAC is pleased to announce the approval of a sole supply agreement with Bayer New Zealand Limited for Mirena, the currently funded brand of progestogen-only long-acting intrauterine system (LIUS). This was the subject of a consultation letter dated 27 June 2016.

In summary, the effect of the decision is that:

•Mirena will continue to be subsidised in the community for the treatment of heavy menstrual bleeding subject to Special Authority criteria.
•Mirena will be listed on the Hospital Medicines List (HML) subject to hospital restrictions for the treatment of heavy menstrual bleeding and endometriosis.
•Mirena would be the only subsidised progestogen-only LIUS in the community; and Mirena will have Hospital Supply Status with a 1% Discretionary Variance (DV) limit in DHB hospitals, from 1 August 2016 until 30 June 2019.
•A confidential rebate will apply which reduces the net price of Mirena (used in both the community and hospital setting) to the Funder.

Details of the decision can be found on PHARMAC's website (http://www.pharmac.govt.nz/news/notification-2016-07-20-lius-mirena/).

Award Date: Wednesday, 20 July 2016 (Pacific/Auckland UTC+12:00)
Date RFx was completed/updated: Monday, 19 October 2015 8:53 AM (Pacific/Auckland UTC+13:00)